Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.

ABSTRACT:

Background

Anti-tumour necrosis factor (anti-TNF) agents are associated with increased infection risk among elderly inflammatory bowel disease (IBD) patients, and thus, alternative biologics may be preferable. However, little comparative data exist on the safety and efficacy of vedolizumab and ustekinumab in elderly IBD patients.

Aims

To compare the safety and effectiveness of ustekinumab and vedolizumab in elderly Crohn's disease patients.

Methods

Patients ≥ 60 years old who commenced ustekinumab or vedolizumab for Crohn's disease (CD) were included. Primary outcome was serious infections, defined as requiring hospitalisation. Efficacy was assessed by treatment persistence and clinical response rates. We appropriately adjusted for confounders using propensity score-m

SUBMITTER: Gebeyehu GG 

PROVIDER: S-EPMC9702964 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature